Gene therapy to treat congestive heart failure gains FDA fast track designation
Bayer AG and its subsidiary Asklepios BioPharmaceutical announced the FDA granted fast track designation for its investigational gene therapy for the treatment of congestive heart failure. The fast track designation is granted to therapies with the potential to fill unmet needs of patients with serious medical conditions. It includes the ability for the developer to have more frequent